PI Industries Limited — PPTs, 07-03-2025: Investor Presentation

PI Industries has hosted an Investor and Analyst Meet to present its strategic transformation initiatives and financial health.

**Financial Highlights:** The company reported strong revenue growth with a CAGR of approximately 20% over the past two decades, reaching ₹7,145 Cr. EBITDA margins remain stable at over 25%, supported by a surplus cash position of ₹4,209 Cr as of December 2024.

**Strategic Initiatives and Growth Drivers:** With a robust pipeline of over 60 molecules, more than 50% are in advanced development stages. The company's strategic shift aims to transition from AgChem leadership to a Life Sciences powerhouse, emphasizing innovation in Biologicals, Electronic Chemicals, and Pharmaceuticals.

**Business Developments:** PI Industries maintains strategic partnerships with global innovators, enhancing its market position. The company’s revenue from proprietary products exceeds 70%, showcasing its capability to drive repeat business through unique solutions.

**Market Position and Competitive Advantage:** Recognized for its strong governance standards, with 44% of the board comprising independent directors, PI Industries continues to uphold its reputation for trust and reliability, securing its status among the top players in the global AgChem market.

**Investor Implications:** The outlook remains positive, with significant potential for growth in both traditional AgChem and new markets like Biologicals and Pharma CRDMO, suggesting an attractive opportunity for investors.